Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Clin Cancer Res. 2016 Jun 22;22(24):6118–6128. doi: 10.1158/1078-0432.CCR-15-3099

Figure 2.

Figure 2

CSF-1R blockade impairs CLL B-cell survival. (A) PBMC from CLL patients (n=10) were cultured in the presence or absence of an isotype control or antagonistic anti-CSF-1R, anti-IL-10, or anti-IL-6 monoclonal antibody. Viability of CD5+CD19+ CLL cells (gates shown) was determined by Annexin V/PI staining. A representative example is shown (A) and the data summarized in B. (C, D) CLL PBMC were cultured in the presence of ibrutinib (1 μM) or vehicle control (DMSO). An isotype control or anti-CSF-1R antibody was included, as indicated. Viability of CD5+CD19+ CLL B cells was determined by Annexin V/PI staining (representative example shown in C). Data obtained from paired samples (n=10) is summarized in D.